AB0849 Correlation between rapid3 and promis10 in patients with ankylosing spondylitis
Authors: A. Ogdie, W.B. Nowell, R. Reynolds, K. Gavigan, S. Venkatachalam, M. de la Cruz, E. Flood, E.J. Schwartz, B. Romero, Y. Park
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Patient-reported outcome (PRO) measures are important in managing and improving the quality of care in patients with chronic rheumatic conditions including ankylosing spondylitis (AS). The RAPID3 was developed for use in patients with rheumatoid arthritis, but it has shown good correlation with the BASDAI and ASDAS in patients with AS.<sup>1</sup> The PROMIS10 is a universal (non-disease specific) PRO measure that quantifies physical and mental health;<sup>2</sup> validity of PROMIS10 has not been examined in patients with AS. <h3>Objectives</h3> To evaluate the relationship between RAPID3 and PROMIS10 in patients with AS. <h3>Methods</h3> US patients aged ≥18 years with a self-reported diagnosis of AS were recruited through CreakyJoints (www.CreakyJoints.org), an online patient support community comprising patients with arthritis and arthritis-related diseases and their caregivers and via outreach on social media. Respondents completed a web-based survey designed to collect data on socio-demographics and clinical symptoms, RAPID3, and PROMIS10. The RAPID3 score consists of three patient self-reported scores (0–10): functional impairment, pain, and patient global assessment; total scores≤3.0=near remission, 3.1 to 6.0=low disease severity, 6.1 to 12.0=moderate disease severity, and ≥12.1 = high disease severity. PROMIS10 is a 10-item questionnaire measuring physical, mental, and social domains; physical and mental health domain scores are transformed to T-score distributions normalised to the general population (mean score=50). PROMIS10 individual scores and global physical and mental health T-scores were stratified by RAPID3 disease severity and compared across RAPID3 severity levels using Kruskal-Wallis or ANOVA or tests, respectively. Spearman's correlation coefficient was calculated between the RAPID3 total score and the PROMIS10 physical health and mental health T-scores, respectively. <h3>Results</h3> Among 235 respondents, 174 (74%) were female, with a mean (SD) age of 49.8 (10.7) years. The mean (SD) RAPID3 cumulative score was 15.4 (5.4) The mean (SD) PROMIS10 global physical and mental health T-scores were 35.60 (7.39) and 39.89 (8.76), respectively, with individual domain scores and global T-scores decreasing with worsening RAPID3 disease activity (table 1; p<i>&lt;</i>0.0001 for all). PROMIS10 physical and mental health T-scores showed a showed a strong correlation with RAPID3 (r<i><sub>s</sub></i>=−0.84 and −0.63, respectively). <h3>Conclusions</h3> RAPID3 and PROMIS10 are relatively short questionnaires that can be used in the real world to track and monitor disease symptoms and health-related quality of life in patients with AS. RAPID3 and PROMIS10 were strongly correlated in patients with AS; although, the PROMIS mental health T-score likely measures a slightly different construct than RAPID3. <h3>References</h3> [1] Orbai A-M, Ogdie A. Rheum Dis Clin North Am. 2016;42(2):265–83. [2] Hays RD, et al. Qual Life Res. 2009;18(7):873–80. <h3>Acknowledgements</h3> This study was sponsored by Novartis Pharmaceuticals Corporation, East Hanover, NJ. <h3>Disclosure of Interest</h3> A. Ogdie Grant/research support from: Pfizer and Novartis, Consultant for: Abbvie, BMS, Eli Lilly and Company, Novartis, Takeda, and Pfizer, W. B. Nowell Employee of: Global Healthy Living Foundation, R. Reynolds: None declared, K. Gavigan Employee of: Global Healthy Living Foundation, S. Venkatachalam Employee of: Global Healthy Living Foundation, M. de la Cruz Employee of: ICON, E. Flood Employee of: ICON, E. Schwartz Employee of: ICON, B. Romero Employee of: ICON, Y. Park Employee of: Novartis Pharmaceuticals Corporation